Axalbion

Axalbion is a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic sensory disorders by targeting TRP (Transient Receptor Potential) ion channels. The company's primary focus is on TRPM8 agonists, a class of molecules that can normalize sensory reflexes in the throat and eye to treat conditions with high unmet needs. Their lead candidate, AX-8, is being developed as a topical treatment for refractory chronic cough and dry eye disease. By leveraging the cooling and desensitizing properties of TRPM8 activation, Axalbion aims to provide rapid-onset relief and disease-modifying potential for patients who currently have limited therapeutic options.